EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Valosin-Containing Protein Contributes to Plexiform Neurofibroma Formation and Represents a Novel Therapeutic Target

Lalitha Gopalan iD, Youjin Na, Liang Hu, Ashley Hall, Mi-Ok Kim iD, Eva Dombi iD, Sara Szabo iD, Nancy Ratner iD, Gang Huang iD, Jianqiang Wu iD

Cells · 06.05.2026 · 15 (9) · 848

DOI: 10.3390/cells15090848 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 06.05.2026. Verfasst von Lalitha Gopalan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Hematology and Cancer Biology, Cancer & Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet…. Hauptthemen laut MEDLINE: Valosin Containing Protein, Neurofibroma, Plexiform. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health, NIH, University of Cincinnati.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurofibromatosis type 1 (NF1) patients are predisposed to develop plexiform neurofibromas (PNFs). By cross-comparison of RNA sequencing and RUNX1-CHIP sequencing data on mouse PNFs, we found that transcripts encoding the NF1-interacting p97/valosin-containing protein (VCP) gene are overexpressed in PNFs. Co-immunoprecipitation confirmed that VCP bounded to neurofibromin. Western blot and immunostaining confirmed VCP overexpression in both mouse and human PNFs. Treatment of primary mouse PNF Schwann cells with CB-5083, a p97/VCP inhibitor, led to accumulation of poly-ubiquitinated proteins and generation of irresolvable proteotoxic stress. Pharmacological or genetic inhibition of VCP reduced mouse PNF cell-derived sphere number, and genetic inhibition of Vcp in Schwann cell precursors decreased tumor-like lesion numbers in a cell transplantation model. In vivo treatment with CB-5083 in Nf1fl/fl;DhhCre PNF mice significantly inhibited cell proliferation, increased cell apoptosis and reduced PNF volume. The combination with a MEK inhibitor did not increase efficacy compared to the single agent, supporting the hypothesis that VCP functions in parallel to, and may be modulated by, RAS–MAPK signaling under stress or oncogenic conditions. The significant effects of VCP inhibition in this pre-clinical study suggest a potential novel therapy for patients with PNFs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Valosin Containing ProteinNeurofibroma, PlexiformAnimalsHumansMiceSchwann CellsCell ProliferationApoptosisNeurofibromin 1Neurofibromatosis 1IndolesPyrimidines

Stichwörter der Autor:innen

CB-5083PD0325901Schwann cellneurofibrominp97/VCPplexiform neurofibroma

Substanzen

Valosin Containing ProteinCB-5083Vcp protein, mouseVCP protein, humanNeurofibromin 1IndolesPyrimidines

Autor:innen und Institutionen

  • Division of Experimental Hematology and Cancer Biology, Cancer & Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH 45229, USA.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, 1450 3rd Street, San Francisco, CA 94143, USA.
  • Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
  • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA.
  • Department of Pediatric Pathology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45267, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

ORCID-Profile: Lalitha Gopalan, Mi-Ok Kim, Eva Dombi, Sara Szabo, Nancy Ratner, Gang Huang, Jianqiang Wu

Förderung

  • National Institute of Health
  • NIH
  • University of Cincinnati
  • Cincinnati Children’s Hospital Center for Clinical & Translational Science & Training

Zitieren

APA

Gopalan, L., Na, Y., Hu, L., Hall, A., Kim, M. O., Dombi, E., Szabo, S., Ratner, N., Huang, G., & Wu, J. (2026). Valosin-Containing Protein Contributes to Plexiform Neurofibroma Formation and Represents a Novel Therapeutic Target. Cells, 15(9), 848. https://doi.org/10.3390/cells15090848

Vancouver

Gopalan L, Na Y, Hu L, Hall A, Kim MO, Dombi E, et al. Valosin-Containing Protein Contributes to Plexiform Neurofibroma Formation and Represents a Novel Therapeutic Target. Cells. 2026;15(9):848. doi:10.3390/cells15090848

BibTeX
@article{Gopalan2026,
  author = {Gopalan, Lalitha and Na, Youjin and Hu, Liang and Hall, Ashley and Kim, Mi-Ok and Dombi, Eva and Szabo, Sara and Ratner, Nancy and Huang, Gang and Wu, Jianqiang},
  title = {Valosin-Containing Protein Contributes to Plexiform Neurofibroma Formation and Represents a Novel Therapeutic Target},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {9},
  pages = {848},
  doi = {10.3390/cells15090848}
}
Kostenlos starten →